Read more
5:14 PM · 23 August 2021

Drug makers shares rose after FDA grants full approval to Pfizer's Covid-19 vaccine

-
-
Open account Download free app
-
-
Open account Download free app
-
-
Open account Download free app

Pfizer (PFE.US), BioNTech (BNTX.US) shares rose 3% and 11% respectively after FDA granted full U.S. approval of their Covid-19 vaccine for use in people aged 16 and older. FDA had been under rising pressure from the scientists and advocacy groups to fully approve Pfizer and BioNTech’s vaccine ever since both companies submitted their application to the agency in early May. Now FDA officials hope that today's approval will convince more unvaccinated Americans that Pfizer's shot is safe and effective. "While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," said Janet Woodcock, the FDA's acting commissioner. Additionally, the U.K. has signed a deal for an additional 35 million vaccines from the two companies. Meanwhile Moderna (MRNA.US) is also in the process of applying for full FDA approval of its Covid-19 vaccine and its shares jumped over 6%.

BioNTech (BNTX.US) stock launched today's session with a bullish price gap and is currently approaching the major resistance zone around $400.00 which coincides with 23.6% Fibonacci retracement of the last upward wave and upper limit of the 1:1 structure. Should break higher occur, then upward move may accelerate towards all-time high at $463.80. On the other hand, the key support zone lies between $330.00 and $362.00 levels. Source: xStation5

12 February 2026, 7:03 PM

Daily summary: Silver plunges 9% 🚨Indices, crypto and precious metals under pressure

12 February 2026, 4:32 PM

Does the current sell-off signal the end of quantum companies?

12 February 2026, 3:58 PM

Howmet Aerospace surges 10% after earnings reaching $100 bilion market cap 📈

12 February 2026, 3:40 PM

US Open: Cisco Systems slides 10% after earnings 📉 Mixed sentiments on Wall Street

Join over 2 000 000 XTB Group Clients from around the world
The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissão de Valores Mobiliários (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits